Clinical trials: Kidney (Renal Cell) Cancer
Melanoma, Prostate Cancer
A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors
This is a first-in-human, open-label, dose escalation study to evaluate the safety and tolerability of pegilodecakin in participants with advanced solid tumors, dosed daily subcutaneously as a monotherapy or in combination with…
- Conditions
- Melanoma, Prostate Cancer, Ovarian Cancer, Renal Cell Carcinoma
- Trial name
- IVY (NCT02009449)
- Testing
- Pegilodecakin, Paclitaxel or Docetaxel and Carboplatin or Cisplatin, FOLFOX (Oxaliplatin/Leucovorin/5-Fluorouracil)
- Where
- 10 sites in United States
- Volunteers
- 353 people
- Sponsor
- Eli Lilly and Company
Neoplastic Cells, Circulating
The Detection of Circulating Tumor Cells (CTCs) in Patients With Renal Cancer Undergoing Cryosurgery Combined With DC-CIK Treatment
Circulating tumor cells (CTCs) have the potential to provide a surrogate for'real-time biopsy' of tumor biological activity. Enumeration and molecular characterization of CTCs in renal cancer could play an important role in…
- Trial name
- NCT02450448
- Testing
- Flow cytometry (FCM), RT-PCR
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Fuda Cancer Hospital, Guangzhou
Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma
Testing of Bevacizumab, Erlotinib, and Atezolizumab in Combination for Advanced-Stage Kidney Cancer
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started…
- Conditions
- Hereditary Leiomyomatosis and Renal Cell Carcinoma, Papillary Renal Cell Carcinoma, Renal Cell Carcinoma, Sporadic Papillary Renal Cell Carcinoma
- Trial name
- NCT04981509
- Testing
- Atezolizumab, Bevacizumab, Biopsy Procedure
- Where
- 13 sites in United States
- Volunteers
- 65 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Transitional Cell, Urinary Bladder Neoplasms
A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer
This study will test an experimental drug (enfortumab vedotin) alone and with different combinations of anticancer therapies. Pembrolizumab is an immune checkpoint inhibitor (CPI) that is used to treat patients with cancer of the…
- Conditions
- Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms, Renal Pelvis Neoplasms
- Trial name
- EV-103 (NCT03288545)
- Testing
- enfortumab vedotin (EV), pembrolizumab, cisplatin
- Where
- 106 sites in United States, Canada and 4 more
- Volunteers
- 348 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Kidney Cancer
Studying Tumor Tissue Samples From Patients Who Have Undergone Surgery for Localized Kidney Cancer
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer.
- Trial name
- NCT00908739
- Testing
- gene expression analysis, immunohistochemistry staining method, laboratory biomarker analysis
- Sponsor
- Case Comprehensive Cancer Center
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
Fluorouracil in Treating Patients With Recurrent or Metastatic Bladder Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of fluorouracil given as a continuous infusion in treating…
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00003175
- Testing
- fluorouracil
- Where
- 62 sites in Brazil, Canada and 6 more
- Volunteers
- 45 people
- Sponsor
- Medical Research Council
Bladder Cancer, Breast Cancer
Irinotecan Plus Gemcitabine in Treating Patients With Unresectable or Metastatic Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Bladder Cancer, Breast Cancer, Colorectal Cancer, Kidney Cancer
- Trial name
- NCT00004095
- Testing
- gemcitabine hydrochloride, irinotecan hydrochloride
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Northwestern University
Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma
Eribulin Mesylate in Treating Patients With Locally Advanced or Metastatic Cancer of the Urothelium and Kidney Dysfunction
This phase I/II trial studies the effect of eribulin mesylate and to see how well it works in treating patients with cancer of the urothelium that has spread to nearby tissue (locally advanced) or to other places in the body…
- Conditions
- Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Recurrent Urothelial Carcinoma
- Trial name
- NCT00365157
- Testing
- Eribulin Mesylate, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 26 sites in United States
- Volunteers
- 168 people
- Sponsor
- National Cancer Institute (NCI)
Carcinoma, Renal Cell
Study of Nexavar (Sorafenib, BAY 43-9006) in Patients With Advanced Refractory Cancer
The purpose of the study is to: Find out if BAY 43-9006 prevents the growth of tumors For patients who have stable cancer status after 3 months of treatment if it is safer and/or more effective to continue to give BAY 43-9006 or…
- Trial name
- NCT00079612
- Testing
- Sorafenib (Nexavar, BAY43-9006)
- Where
- 7 sites in United States, United Kingdom
- Volunteers
- 501 people
- Sponsor
- Bayer
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0306, Irinotecan in Treating Patients With Recurrent or Refractory Advanced Transitional Cell Cancer of the Urothelium Previously Treated With Chemotherapy
RATIONALE: Drugs used in chemotherapy such as irinotecan use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00066612
- Testing
- irinotecan hydrochloride
- Volunteers
- 45 people
- Sponsor
- SWOG Cancer Research Network
Clear Cell Renal Cell Carcinoma, Cervical Carcinoma
A Safety and Efficacy Study Evaluating CTX131 in Adult Subjects With Relapsed or Refractory Solid Tumors
This is an open-label, multicenter, Phase 1/2 study evaluating the safety and efficacy of CTX131™ in subjects with relapsed or refractory solid tumors.
- Conditions
- Clear Cell Renal Cell Carcinoma, Cervical Carcinoma, Esophageal Carcinoma, Pancreatic Adenocarcinoma
- Trial name
- NCT05795595
- Testing
- CTX131
- Where
- 7 sites in United States
- Volunteers
- 19 people
- Sponsor
- CRISPR Therapeutics AG
Bone Cancer, Chondrosarcoma
Therapeutic Angiotensin-(1-7) in Treating Patients With Metastatic Sarcoma That Cannot Be Removed By Surgery
This phase II trial studies how well therapeutic angiotensin-(1-7) works as second-line therapy or third-line therapy in treating patients with metastatic sarcoma that cannot be removed by surgery.
- Conditions
- Bone Cancer, Chondrosarcoma, Clear Cell Sarcoma of the Kidney, Metastatic Osteosarcoma
- Trial name
- NCT01553539
- Testing
- therapeutic angiotensin-(1-7), laboratory biomarker analysis
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Wake Forest University Health Sciences
Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma
A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)
The main purpose of this study is to compare the objective response rate (ORR) and overall survival (OS) of bempegaldesleukin (NKTR-214: BEMPEG) combined with nivolumab to that of tyrosine kinase inhibitor (TKI) monotherapy…
- Trial name
- NCT03729245
- Testing
- bempegaldesleukin, sunitinib, nivolumab
- Where
- 96 sites in United States, Argentina and 8 more
- Volunteers
- 623 people
- Sponsor
- Nektar Therapeutics
Kidney Cancer
Sequential Two-agent Assessment in Renal Cell Carcinoma Therapy: The START Trial
The goal of this clinical research study is to compare 6 different 2-drug "sequences" of everolimus, bevacizumab, or pazopanib to learn how they may affect metastatic kidney cancer.
- Trial name
- NCT01217931
- Testing
- Pazopanib, Bevacizumab, Everolimus
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- M.D. Anderson Cancer Center
Transitional Cell Carcinoma, Renal Cell Cancer
Relationship of Ochratoxin A to Upper Urologic Cancers
This pilot study will explore the relationship of Ochratoxin A (OTA) levels in patients with upper tract transitional cell (TCC), renal cell, and testicular cancers by measuring levels of OTA in serum and tumor samples.
- Conditions
- Transitional Cell Carcinoma, Renal Cell Cancer, Testicular Cancer
- Trial name
- NCT00216801
- Where
- Canada
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Renal Cell Carcinoma
PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma
Given the growing importance of anti-angiogenic therapies in the treatment of metastatic renal carcinoma, it is expected that this trial will establish the preliminary data needed to apply for funding of a larger clinical…
- Trial name
- NCT01502228
- Testing
- 150-Water, 62Cu-ethylglyoxal bis, Positron Emission Tomography
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Indiana University
Kidney Cancer
Combination Chemotherapy Alone or With Radiation Therapy in Treating Children With Kidney Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high energy x-rays to damage tumor cells.
- Trial name
- NCT00002611
- Testing
- dactinomycin, filgrastim, cyclophosphamide
- Where
- 235 sites in United States, Australia and 5 more
- Volunteers
- 3,031 people
- Sponsor
- Children's Oncology Group
Renal Cell Carcinoma
Efficacy and Safety Comparison of RAD001 Versus Sunitinib in the First-line and Second-line Treatment of Patients With Metastatic Renal Cell Carcinoma
This study assessed the efficacy and safety of first-line RAD001 followed by second-line sunitinib versus the opposite sequence: first-line sunitinib followed by second-line RAD001 for the treatment of patients with MRCC.
- Trial name
- RECORD-3 (NCT00903175)
- Testing
- everolimus, sunitinib
- Where
- 84 sites in United States, Argentina and 17 more
- Volunteers
- 471 people
- Sponsor
- Novartis Pharmaceuticals
Adenocarcinoma, Prostate Neoplasms
Use of Tracking Devices to Locate Abnormalities During Invasive Procedures
This study will evaluate the accuracy and effectiveness of an experimental tracking device for locating abnormalities during invasive procedures, such as biopsy or ablation, that cannot easily be visualized by usual imaging…
- Conditions
- Adenocarcinoma, Prostate Neoplasms, Prostate Cancer, Renal Cell Carcinoma
- Trial name
- NCT00102544
- Testing
- EM Tracking
- Where
- United States
- Volunteers
- 3,894 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Kidney Cancer, Melanoma (Skin)
Positron Emission Tomography and CT Scan in Predicting Response in Patients With Metastatic Melanoma or Kidney Cancer Who Are Undergoing Cellular Adoptive Immunotherapy on a Surgery Branch Clinical Trial
RATIONALE: Diagnostic procedures, such as positron emission tomography and computed tomography scan (done before and after cellular adoptive immunotherapy), may help doctors predict a patient's response to treatment and help plan…
- Trial name
- NCT00316901
- Testing
- computed tomography, positron emission tomography, fludeoxyglucose F 18
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.